

Corrigendum: What's fueling the biotech engine—2007

Saurabh Aggarwal

Nat. Biotechnol. 26, 1227–1233 (2008); published online 7 November 2008; corrected after print 9 February 2009

In the version of this article initially published, 2007 US sales of therapeutic enzymes in Figure 3 were incorrectly listed as \$0.7 billion. They should be \$0.9 billion. In the same figure, the 2007 growth (%) was incorrectly listed as –14%; it should be 18%. On page 1230, human growth hormone sales growth rate was incorrectly reported as 45%; it should be 5%. The errors have been corrected in the PDF and HTML versions of this article.

Erratum: What's fueling the biotech engine—2007

Saurabh Aggarwal

Nat. Biotechnol. 26, 1227–1233 (2008); published online 7 November 2008; corrected after print 9 February 2009

In the version of this article initially published, in Figure 5, the \$2.40 billion pie section was mislabeled as Rituxan. It should be Procrit. The error has been corrected in the PDF and HTML versions of this article.

Erratum: Asymmetric RNA duplexes mediate RNA interference in mammalian cells

Xiangao Sun, Harry A Rogoff & Chiang J Li

Nat. Biotechnol. 26, 1379–1382 (2008); published online 23 November 2008; corrected after print 9 February 2009

In the version of this article initially published, on page 1379, column 2, line 7, a parenthesis was misplaced. "...the passenger (often the sense strand)" should have read, "...the passenger (often the sense) strand". The error has been corrected in the HTML and PDF versions of the article.

Erratum: Profile: Alan Alda

George S Mack

Nat. Biotechnol. 26, 1325 (2008); published online 5 December 2008

In the print version of this article, the photo of Alan Alda was erroneously credited. The photo was taken by Alan Alda.

Erratum: Biotech sector ponders potential 'bloodbath'

Peter Mitchell & Brady Huggett

Nat. Biotechnol. 27, 3–5 (2009); published online 8 January 2009; corrected after print 9 February 2009

In the version of this article initially published, we neglected to define our categories for public biotech firms. In the following definitions, the dollar amounts refer to a firm's market capitalization or 'cap': microcap, <\$250 million; small cap, \$250 million to <\$1 billion; mid-cap, \$1 billion to <\$5 billion; large cap, ≥\$5 billion. The definitions have been added to Box 2, Figure 1 legend, in the HTML and PDF versions of the article.

Erratum: Doubts surround link between *Bt* cotton failure and farmer suicide

Cormac Sheridan

Nat. Biotechnol. 27, 9–10 (2009); published online 8 January 2009; corrected after print 9 February 2009

In the version of this article initially published, in column 3, line 3 in the last paragraph, Debdatta Sengupta was referred to as "he." The text should have read "she" as Sengupta is a woman. The error has been corrected in the HTML and PDF versions of the article.